Navigation Links
An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market
Date:6/23/2009

Emerging Combination Products from GlaxoSmithKline/Theravance, Boehringer Ingelheim and Novartis Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a 28 percent increase in the diagnosed prevalent population will drive growth in the chronic obstructive pulmonary disease (COPD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Despite market constraints that include currently low diagnosis rates, pricing and reimbursement restrictions and challenging regulatory landscapes, the COPD drug market will grow by nearly $4.3 billion from 2008 to 2018.

The new Pharmacor report entitled Chronic Obstructive Pulmonary Disease finds that maintenance therapies dominated the COPD market in 2008 as nearly 80 percent of COPD sales were generated by such agents. Although safety concerns are associated with several maintenance therapies commonly prescribed for COPD, including ICS-containing products as well as inhaled anticholinergics, physicians indicate that they will continue to widely prescribe these drugs to their COPD patients but will remain vigilant in monitoring the safety of these drugs in their patients who receive them. The report finds that as new long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) combinations, long-acting muscarinic antagonists (LAMAs), and LABA/LAMA products emerge from clinical development over the next decade, the use of maintenance therapies will continue to increase.

Several once-daily dosed LABAs such as Novartis's indacaterol, Boehringer Ingelheim's BI-1744-CL and GlaxoSmithKline/Theravance's GW-642444 will also enter the COPD market over the next decade. The report finds that these emerging once-daily LABAs will be the cornerstones of combination product development programs which will result in new LABA/ICSs and LABA/LAMAs, the latter being a new and promising class of combination drugs. While all of these agents will achieve their greatest potential as components of combination products, drug marketers are expected to position these agents as add-on therapy to LAMA treatment and/or as monotherapies for first-line use in patients with moderate COPD in order to maximize the commercial potential of these molecules.

"While Advair and Spiriva dominated the COPD market in 2008, we expect their share of the COPD market to decrease through 2018," said Decision Resources Analyst Regina Jammen, M.Sc. "As new maintenance therapies and non-innovator versions of several market-leading branded products launch, the COPD market will shift from a few key products to numerous therapies with subsequently less market concentration on only a few brands. However, even with these changes to the market landscape, the unmet need remains for drugs that can dramatically reduce exacerbation rates and/or slow or halt the progression of COPD."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                      Decision Resources, Inc.
    Christopher Comfort                     Elizabeth Marshall
    781-296-2597                            781-296-2563
    ccomfort@dresources.com                 emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. U.S. Army Increases Medical and Dental School Benefits
2. A 50% Increase in Medical Bankruptcies - A Worry for Adults Assisting Aging Parents
3. Winner Medical to Benefit From the Increase of Tax Rebate Rate for Exports From China
4. Hodgkin lymphoma survivors have increased risk of stroke and transient ischemic attack
5. No Matter the Vehicle, Sending Text Messages While Driving Increases Risk of Accidents, Warns New York Auto Accident Lawyer
6. Hartford grants increase support for geriatric social work training
7. Study Shows Increases in Working After 65 and Using Commercial Insurance
8. Depression may increase Alzheimers risk in people with memory problems
9. Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
10. Colonoscopy Risks Increase With Age and Illness
11. For Men Over 50, Odds of Eye Discomfort Increases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: